Navigation Links
TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments
Date:5/13/2008

LA JOLLA, Calif., May 13 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today reported its financial results and accomplishments for the first quarter ended March 31, 2008. For the three-month period, the company posted revenue of $2.0 million and a net loss of $3.9 million. Cash and cash equivalents totaled $25.7 million at March 31, 2008.

"We have been diligently executing on the strategic plan outlined in February, maximizing the value of our versatile compounds while prudently managing our resources," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "The role of glutamate in disease has been garnering much attention, further supporting the value of tezampanel and NGX426, our two ionotropic glutamate receptor antagonists. We are focused on developing better alternatives to current therapies and our pipeline reflects this effort, particularly as we move tezampanel toward the clinic in muscle spasticity and rigidity, our first non-pain indication for the drug, and with the recent initiation of a Phase II clinical trial evaluating NGX267 in xerostomia. Furthermore, the recent clinical guidance call held with the FDA supports the advancement of tezampanel in acute migraine."

First Quarter 2008 and Recent Accomplishments:

-- Held a clinical guidance teleconference with the U.S. Food and Drug

Administration (FDA) and confirmed that it has no objection to

TorreyPines moving forward into Phase III clinical trials for the

treatment of acute migraine with the 40 mg dose of tezampanel. Prior

to initiating any Phase III clinical trials, TorreyPines intends to

hold an end-of-Phase II meeting with the FDA, currently planned for


'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. TorreyPines Therapeutics to Present at the JMP Securities Healthcare Focus Conference
2. TorreyPines Therapeutics to Present at BMO Capital Markets Focus on Healthcare Conference
3. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
4. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
5. Prime Therapeutics Receives TIPPS Certification
6. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
7. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
8. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
9. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
10. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
11. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... It’s been called “cosmetics heaven,” “mecca for make-up,” ... Naimie’s Beauty Center in LA. Now MENAJI is part of that experience acting as ... Beauty Center has been a favorite of makeup artists and hair pros as well ...
(Date:8/4/2015)... Port Washington, NY (PRWEB) , ... August 04, ... ... the 2015 Midyear Channel Report, finds the North America IT reseller channel will ... and profitability at rates ahead of their 2014 pace and greater than their ...
(Date:8/4/2015)... ... August 04, 2015 , ... Data2Life , a ... designed to provide pharmaceutical and healthcare organizations with advanced intelligence on drug effects. ... from regulatory filings (including the FDA and HealthCanada), social media and anonymized clinical ...
(Date:8/4/2015)... New York, NY (PRWEB) , ... August 04, ... ... FHA multifamily mortgage lender specializing in healthcare finance, announced the closing of a ... operates a two campus health system located in Smithfield and Clayton, North Carolina. ...
(Date:8/4/2015)... DC (PRWEB) , ... August 04, 2015 , ... Updated ... Inc.’s (AIS) in-house research team, can now be accessed at http://www.AISHealth.com . The ... AIS’s Directory of Health Plans: 2015, the tables and charts on the website’s “Data” ...
Breaking Medicine News(10 mins):Health News:MENAJI Shines in Make-Up Mecca for Stars 2Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 2Health News:The 2112 Group Forecasts North America IT Channel to Grow At Least 6% in 2015 3Health News:Data2Life Announces New System for Advance Intelligence on Drug Events 2Health News:Data2Life Announces New System for Advance Intelligence on Drug Events 3Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2
... 13 Abbott announced new data from,the open-label ... and Safety in AS) phase III clinical trial, ... of ankylosing,spondylitis (AS) for up to three years ... is a type of arthritis that primarily causes,inflammation ...
... - June 13, 2008 - UT Southwestern Medical ... weight-loss surgery in Texas. , Rather than the ... gastric banding surgery, surgeons used a single 8-centimeter ... "There,s a current revolution in minimally invasive surgery: ...
... of Mesothelioma Victim Will Address Effort to Find ... Lexi,Miletto, whose grandfather, Joseph Miletto died in 2005 ... the Gala Dinner on Friday,evening, June 27th, part ... Malignant Mesothelioma, which runs Thursday,June 26th through Saturday, ...
... Health System to Use Valuable Patient Care,Resources in Manner ... Hundreds of Healthcare,workers from Los Angeles and Orange ... & Lardner, LLP on Thursday, June 12th to protest ... at St. Joseph Health System (SJHS), a $3.4 billion ...
... State Projected to Lose $6.2 Million in Economic ... 12 As Congress returned to,Washington this week ... Health Care Association (NHCA) released a new analysis ... A national,nursing home funding cuts will not only ...
... Dismayed by Senate Vote to Block Medicare Improvement ... for Prevention, Mental,Health and Low-Income Programs, Boosted Quality ... a minority of the,U.S. Senate blocked critical legislation ... Americans who depend on it. The Medicare Improvements,for ...
Cached Medicine News:Health News:Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years 2Health News:Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years 3Health News:Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years 4Health News:Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years 5Health News:Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years 6Health News:UT Southwestern surgeons complete first single-incision lap-band surgery in Texas 2Health News:Asbestos Tragedy and Hope 2Health News:Caregivers Protest Foley & Lardner's Union Busting & Intimidation 2Health News:Caregivers Protest Foley & Lardner's Union Busting & Intimidation 3Health News:New NV Economic Study: Bush Medicare Cuts Undermine State and Local Economic, Jobs Base 2Health News:New NV Economic Study: Bush Medicare Cuts Undermine State and Local Economic, Jobs Base 3Health News:AARP Georgia Key Vote News Alert 2Health News:AARP Georgia Key Vote News Alert 3
(Date:8/4/2015)... 2015  Ironshore Pharmaceuticals & Development, Inc. ("Ironshore") ... company specializing in personalized medicine, to participate in ... to evaluate the safety and efficacy of HLD-200, ... disorder (ADHD). This is Restore,s second clinical trial ... partnered with Ironshore in 2014 and continues to ...
(Date:8/3/2015)... 2015  Luminex Corporation (NASDAQ: LMNX ) today ... 30, 2015.  Financial and operating highlights for the quarter ... 2015 revenue by 6 percent to $58.9 million, over ... quarter 2015 assay revenue by 22 percent to $24.2 ... , Increased Q2 2015 royalty revenue by 17 ...
(Date:8/3/2015)... -- DURECT Corporation (Nasdaq: DRRX ) announced today financial results ... million and net loss was $5.5 million for the three ... of $4.6 million and net loss of $5.5 million for ... we had cash and investments of $37.8 million, compared to ... At June 30, 2015, we had $19.8 million in long ...
Breaking Medicine Technology:Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 3Luminex Corporation Reports Record 2nd Quarter 2015 Results 4Luminex Corporation Reports Record 2nd Quarter 2015 Results 5Luminex Corporation Reports Record 2nd Quarter 2015 Results 6Luminex Corporation Reports Record 2nd Quarter 2015 Results 7Luminex Corporation Reports Record 2nd Quarter 2015 Results 8Luminex Corporation Reports Record 2nd Quarter 2015 Results 9Luminex Corporation Reports Record 2nd Quarter 2015 Results 10Luminex Corporation Reports Record 2nd Quarter 2015 Results 11Luminex Corporation Reports Record 2nd Quarter 2015 Results 12Luminex Corporation Reports Record 2nd Quarter 2015 Results 13Luminex Corporation Reports Record 2nd Quarter 2015 Results 14Luminex Corporation Reports Record 2nd Quarter 2015 Results 15Luminex Corporation Reports Record 2nd Quarter 2015 Results 16DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10
... 31st European Cystic Fibrosis Conference -, SOUTH ... /PRNewswire/,-- PTC Therapeutics, Inc. (PTC) today announced promising ... fibrosis (CF). Results from an Israeli Phase 2a,extension ... in adult,patients with nonsense-mutation-mediated CF demonstrated statistically,significant improvements ...
... Data from Positive Phase 2a Trial, WALTHAM, ... ) today announced that based on feedback from ... initiate a Phase 2b clinical,trial of RG2417, an ... later this year. This will be a multi-center, ...
Cached Medicine Technology:PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 2PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 3PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 4PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity 5Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 2Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 3Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 4Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder 5
... gives you an entirely new way to visualize, ... DVR is the perfect tool for turning real-life ... and footswitch, you can record only the parts ... hours of reviewing video tapes. With your finished ...
LCD monitors....
The A3 3-Chip Camera includes digital processing, seamless autoshutter, industry-leading reliability, white balance with memory function, ease of operation, and a 2 year warranty....
A lower cost alternative to the flagship A3, the A1 retains the essential characteristics of high quality image, simplicity of operation and reliability....
Medicine Products: